Risks facing GPs as NICE loses power on drug scrips

Paul Corrigan on the pressure on GPs to prescribe drugs regardless of cost.

Paul Corrigan: Without the cover of NICE, GPs face high-risk decisions (Photograph: J Heath Lancy)
Paul Corrigan: Without the cover of NICE, GPs face high-risk decisions (Photograph: J Heath Lancy)

The coalition government has announced a policy that will impact upon the lives of GP commissioners. Currently NICE decides which drugs are cost effective for the NHS.

Health secretary Andrew Lansley said: 'NICE's role will change. It will focus on advising how best to use treatments and to develop quality standards for the NHS, rather than recommending whether patients should be able to access particular drugs. We want patients to have access to the medicines that their clinicians believe are best for them' (Hansard, 2 November 2010).

GP commissioning will give GPs control of the majority of the funding of NHS services, including medicines budgets, which, currently, is the legal responsibility of PCTs.

Local GP leaders recognise that they can reduce the variability of prescribing but at the moment they make these decisions consequent on NICE making decisions about value for money for the NHS as a whole.

They do this with a formula which judges their cost in relationship to the quality of life years that they provide. The NHS has a great interest in drugs at a price that provides good value outcomes.

Pharma companies
This is also vital for pharmaceutical companies. They need to charge as high a price as possible to recoup their development investment.

In some cases, there is a conflict of interest between the NHS and the company. If NICE does not make these value for money decisions, those GPs in charge of their medicines budget will have to make them.

And this is where two aspects of government policy merge.

GPs are being given the responsibility for managing the NHS commissioning budget including the cost of medicines. It will be their responsibility to ensure that NHS resources are spent within that budget.

GPs are being given the responsibility for the decision about medical and financial cost-effectiveness of drugs. It will be the GP who will suffer the media and personal pressure that is at the moment inflicted on NICE to prescribe drugs regardless of value for money for the NHS.

So without NICE value for money judgments, the choice for GPs is clear. Say yes to high-cost drugs and GPs will bust the budget they have been made responsible for. Or say no to high-cost drugs and be attacked as the organisation responsible for worrying about pharmaceutical value for money.

Without the cover of NICE, GPs taking on the responsibility for commissioning will be doing so at very high risk.

  • Paul Corrigan is a management consultant and former adviser to Tony Blair. More at pauldcorrigan.com

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Just published

GP on phone in recorded consultation assessment

Consultation skills to help GP trainees pass the RCA

Dr Afsar Rizvi highlights the key skills GP trainees need to master in order to pass...

Wes Streeting

Labour promises same GP 'each appointment' and face-to-face access if patients want it

A Labour government would offer patients the chance to see 'the same doctor each...

Man wearing mask on train

UK faces serious threat from flu and COVID-19 'twindemic' this winter

There are strong indications the UK faces a dangerous 'twindemic' of COVID-19 and...

NHS sign outside a building

PCN contract overhaul defers two-week appointment target until April 2023

NHS England has announced changes to the network contract DES, including deferring...

Coins

NHS sets out priorities for extra GP funding this winter

Integrated care boards could target extra funding for general practice at phone systems,...

Shadow chancellor Rachel Reeves

Labour promises to double medical school places with tax cut reversal

A Labour government would double medical school places with funding raised from reversing...